Comparison of Breast Cancer Molecular Features and Su Ancestry in The Cancer Genome Atlas

Citation Report

#	ARTICLE	IF	CITATIONS
1	Breast cancer statistics, 2017, racial disparity in mortality by state. Ca-A Cancer Journal for Clinicians, 2017, 67, 439-448.	157.7	1,264
2	Development and clinical application of radiomics in lung cancer. Radiation Oncology, 2017, 12, 154.	1.2	70
3	Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study. Breast Cancer Research, 2017, 19, 131.	2.2	37
4	Insulinâ€like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Medicine, 2018, 7, 616-625.	1.3	5
5	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	13.5	2,277
6	Population-dependent Intron Retention and DNA Methylation in Breast Cancer. Molecular Cancer Research, 2018, 16, 461-469.	1.5	23
7	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nature Communications, 2018, 9, 1725.	5.8	122
8	Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screeningâ€"Reply. JAMA Oncology, 2018, 4, 883.	3.4	0
9	Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening. JAMA Oncology, 2018, 4, 883.	3.4	2
10	Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 3-10.	1.1	26
11	Mutations in context: implications of BRCA testing in diverse populations. Familial Cancer, 2018, 17, 471-483.	0.9	23
12	Breast Cancer Disparities. Surgical Oncology Clinics of North America, 2018, 27, 217-234.	0.6	22
13	Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptorâ€"Positive, Node-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 652-658.	0.8	20
14	Searching for the value of accountable care organizations in cancer care. Cancer, 2018, 124, 4287-4289.	2.0	2
15	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell, 2018, 34, 549-560.e9.	7.7	168
16	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications, 2018, 9, 4181.	5.8	77
17	Decelerated DNA methylation age predicts poor prognosis of breast cancer. BMC Cancer, 2018, 18, 989.	1.1	16
18	LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. Scientific Reports, 2018, 8, 15572.	1.6	26

#	Article	IF	Citations
19	Multicenter Study Using Desorption-Electrospray-Ionization-Mass-Spectrometry Imaging for Breast-Cancer Diagnosis. Analytical Chemistry, 2018, 90, 11324-11332.	3.2	70
20	Breast cancer metastasis through the lympho-vascular system. Clinical and Experimental Metastasis, 2018, 35, 443-454.	1.7	31
21	TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. Npj Breast Cancer, 2018, 4, 13.	2.3	18
22	Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Molecular Carcinogenesis, 2018, 57, 1311-1318.	1.3	6
23	Prioritizing diversity in human genomics research. Nature Reviews Genetics, 2018, 19, 175-185.	7.7	297
24	Evaluation of Surgical Disparities Between African American and European American Women Treated for Breast Cancer Within an Equal-Access Military Hospital. Annals of Surgical Oncology, 2019, 26, 3838-3845.	0.7	10
25	BioDog, biomarker detection for improving identification power of breast cancer histologic grade in methylomics. Epigenomics, 2019, 11, 1717-1732.	1.0	9
26	Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. PLoS ONE, 2019, 14, e0224760.	1.1	6
27	Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study. PLoS ONE, 2019, 14, e0224064.	1.1	16
28	Breast cancer statistics, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 438-451.	157.7	2,068
29	Pathogenic mutations in the ALS gene CCNF cause cytoplasmic mislocalization of Cyclin F and elevated VCP ATPase activity. Human Molecular Genetics, 2019, 28, 3486-3497.	1.4	24
30	Risk Factors for Triple-Negative Breast Cancer among Latina Women. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1771-1783.	1.1	21
31	A functional role for the cancer disparity-linked genes, CRYβB2 and CRYβB2P1, in the promotion of breast cancer. Breast Cancer Research, 2019, 21, 105.	2.2	18
32	Feature selection may improve deep neural networks for the bioinformatics problems. Bioinformatics, 2020, 36, 1542-1552.	1.8	57
33	Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use?. Breast Journal, 2019, 25, 7-8.	0.4	0
34	Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Cancer, 2019, 125, 3225-3233.	2.0	18
35	Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathologica Communications, 2019, 7, 99.	2.4	32
36	Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. International Journal of Cancer, 2019, 145, 3321-3333.	2.3	16

#	ARTICLE	IF	CITATIONS
37	Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. PeerJ, 2019, 7, e6501.	0.9	18
38	PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Scientific Reports, 2019, 9, 7956.	1.6	37
39	Breast cancer subtypes among Eastern‐African‐born black women and other black women in the United States. Cancer, 2019, 125, 3401-3411.	2.0	25
40	Disadvantaged neighborhoods and racial disparity in breast cancer outcomes: the biological link. Cancer Causes and Control, 2019, 30, 677-686.	0.8	55
41	Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. Cancer Cell, 2019, 35, 341-343.	7.7	7
42	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. Breast Cancer Research and Treatment, 2019, 175, 247-259.	1.1	43
43	Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, 304-310.	1.1	13
44	Survival pattern of rare histological types of breast cancer in a Nigerian institution. Pan African Medical Journal, 2019, 34, 114.	0.3	3
45	Pathology of Senegalese breast cancers. Pan African Medical Journal, 2019, 34, 67.	0.3	10
46	Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. PLoS ONE, 2019, 14, e0210372.	1.1	12
47	Differences in microRNA expression in breast cancer between women of African and European ancestry. Carcinogenesis, 2019, 40, 61-69.	1.3	21
48	The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population. Cancer Epidemiology, 2019, 58, 71-76.	0.8	8
49	Big data management challenges in health research‐a literature review. Briefings in Bioinformatics, 2019, 20, 156-167.	3.2	56
50	Effect of Starch Isolation Method on Structural and Physicochemical Properties of Acorn Kernel Starch. Starch/Staerke, 2020, 72, 1900122.	1.1	19
51	Advancing the Science of Cancer in Latinos. , 2020, , .		5
52	A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2⁻ Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, e232-e243.	1.1	29
53	A deep learning and similarity-based hierarchical clustering approach for pathological stage prediction of papillary renal cell carcinoma. Computational and Structural Biotechnology Journal, 2020, 18, 2639-2646.	1.9	11
54	Ancestry-dependent gene expression correlates with reprogramming to pluripotency and multiple dynamic biological processes. Science Advances, 2020, 6, .	4.7	16

#	Article	IF	Citations
55	Methylation-Mediated Silencing of MicroRNA-497 Promotes Breast Cancer Progression Through Up-Regulation of Mucin1. Frontiers in Oncology, 2020, 10, 552099.	1.3	13
56	Breast Cancer in Jamaica: Trends From 2010 to 2014—Is Mortality Increasing?. JCO Global Oncology, 2020, 6, 837-843.	0.8	4
57	Global disparities in breast cancer outcomes: new perspectives, widening inequities, unanswered questions. The Lancet Global Health, 2020, 8, e978-e979.	2.9	13
58	Update on multi-gene panel testing and communication of genetic test results. Breast Journal, 2020, 26, 1513-1519.	0.4	9
59	Understanding breast cancer disparities—a multi-scale challenge. Annals of Translational Medicine, 2020, 8, 906-906.	0.7	8
60	High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients. Journal of Translational Medicine, 2020, 18, 334.	1.8	19
61	Body fatness and mTOR pathway activation of breast cancer in the Women's Circle of Health Study. Npj Breast Cancer, 2020, 6, 45.	2.3	10
62	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers, 2020, 12, 2392.	1.7	171
63	Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival. BMC Medical Genomics, 2020, 13, 116.	0.7	17
64	Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells. Nutrients, 2020, 12, 3755.	1.7	19
65	Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 884-892.	3.0	21
66	Black Lives Matter Worldwide: Retooling Precision Oncology for True Equity of Cancer Care. Cell Reports Medicine, 2020, 1, 100079.	3.3	6
67	Bridging the Gap: The Impact of Genetic Ancestry on Routes to Tumorigenesis. Cancer Cell, 2020, 37, 619-621.	7.7	1
68	Ancestry-specific predisposing germline variants in cancer. Genome Medicine, 2020, 12, 51.	3.6	35
69	Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer. Current Breast Cancer Reports, 2020, 12, 125-131.	0.5	29
70	Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival. Clinical Cancer Research, 2020, 26, 1905-1914.	3.2	18
71	Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women. Breast Cancer Research, 2020, 22, 62.	2.2	24
72	S100A9 as a novel diagnostic and prognostic biomarker in human gastric cancer. Scandinavian Journal of Gastroenterology, 2020, 55, 338-346.	0.6	12

#	Article	IF	Citations
73	High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer. Cancer, 2020, 126, 2217-2224.	2.0	11
74	Next-generation sequencing identifies recurrent copy number variations in invasive breast carcinomas from Ghana. Modern Pathology, 2020, 33, 1537-1545.	2.9	6
75	Silencing of Growth Differentiation Factor-15 Promotes Breast Cancer Cell Invasion by Down-regulating Focal Adhesion Genes. Anticancer Research, 2020, 40, 1375-1385.	0.5	5
76	Comparison of pathway and gene-level models for cancer prognosis prediction. BMC Bioinformatics, 2020, 21, 76.	1.2	13
77	Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genetics, 2020, 16, e1008641.	1.5	78
78	Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?. Breast Cancer Research and Treatment, 2020, 181, 135-144.	1.1	8
79	Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers. Breast Cancer Research and Treatment, 2020, 181, 145-154.	1.1	10
80	Physical activity barriers and resources among black women with a history of breast and endometrial cancer: a systematic review. Journal of Cancer Survivorship, 2020, 14, 556-577.	1.5	15
81	Differences in gene-expression profiles in breast cancer between African and European-ancestry women. Carcinogenesis, 2020, 41, 887-893.	1.3	8
82	Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. Clinical Cancer Drugs, 2020, 7, 3-15.	0.3	2
83	Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes. Cancer Letters, 2021, 500, 64-74.	3.2	5
84	Cancer health disparities in racial/ethnic minorities in the United States. British Journal of Cancer, 2021, 124, 315-332.	2.9	447
85	Epigenetic and Posttranscriptional Modulation of SOS1 Can Promote Breast Cancer Metastasis through Obesity-Activated c-Met Signaling in African-American Women. Cancer Research, 2021, 81, 3008-3021.	0.4	11
86	The influence of evolutionary history on human health and disease. Nature Reviews Genetics, 2021, 22, 269-283.	7.7	133
87	Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer. Cancer Imaging, 2021, 21, 4.	1.2	22
88	Socioeconomic and Surgical Disparities are Associated with Rapid Relapse in Patients with Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2021, 28, 6500-6509.	0.7	16
89	Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. Journal of Personalized Medicine, 2021, 11, 149.	1.1	16
90	Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry. Npj Breast Cancer, 2021, 7, 10.	2.3	11

#	Article	IF	Citations
91	Race and Genetic Ancestry in Medicine â€" A Time for Reckoning with Racism. New England Journal of Medicine, 2021, 384, 474-480.	13.9	371
92	Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancerâ€"Specific Mortality Among US Women. JAMA Oncology, 2021, 7, 370.	3.4	64
93	A transdisciplinary approach to understand the epigenetic basis of race/ethnicity health disparities. Epigenomics, 2021, 13, 1761-1770.	1.0	19
95	Improving reporting standards for polygenic scores in risk prediction studies. Nature, 2021, 591, 211-219.	13.7	265
96	Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity. Clinical and Experimental Metastasis, 2022, 39, 7-14.	1.7	14
97	Dual-energy CT quantitative parameters for the differentiation of benign from malignant lesions and the prediction of histopathological and molecular subtypes in breast cancer. Quantitative Imaging in Medicine and Surgery, 2021, 11, 1946-1957.	1.1	16
98	Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer, 2021, 21, 568.	1.1	10
99	Racial and Ethnic Disparities in Breast Cancer Survival. Annals of Surgery, 2021, 274, e269-e275.	2.1	14
100	Disparities in Breast Cancer Associated With African American Identity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e29-e46.	1.8	27
101	Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. STAR Protocols, 2021, 2, 100483.	0.5	2
102	HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers, 2021, 13, 2824.	1.7	117
103	Revisiting social MPE: an integration of molecular pathological epidemiology and social science in the new era of precision medicine. Expert Review of Molecular Diagnostics, 2021, 21, 869-886.	1.5	2
104	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 797-804.	2.3	11
105	Disparities in Surgical Oncology: Management of Advanced Cancer. Annals of Surgical Oncology, 2021, 28, 8056-8073.	0.7	5
106	Oncologic Anthropology: An Interdisciplinary Approach to Understanding the Association Between Genetically Defined African Ancestry and Susceptibility for Triple Negative Breast Cancer. Current Breast Cancer Reports, 2021, 13, 247-258.	0.5	7
107	Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. Annals of Surgical Oncology, 2022, 29, 686-696.	0.7	11
108	Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival. ESMO Open, 2021, 6, 100232.	2.0	19
109	Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)â€"Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells. ChemMedChem, 2021, 16, 3280-3292.	1.6	3

#	ARTICLE	IF	CITATIONS
110	ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nature Communications, 2021, 12, 4867.	5.8	97
111	A systematic review of datasets that can help elucidate relationships among gene expression, race, and immunohistochemistry-defined subtypes in breast cancer. Cancer Biology and Therapy, 2021, 22, 1-13.	1.5	2
112	Reporting on Race and Racial Disparities in Breast Cancer. Annals of Surgery, 2023, 277, 329-334.	2.1	5
113	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. Npj Precision Oncology, 2021, 5, 83.	2.3	4
114	Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer. Oncologist, 2021, 26, 910-915.	1.9	13
115	Somatic mutations of triple-negative breast cancer: a comparison between Black and White women. Breast Cancer Research and Treatment, 2020, 182, 503-509.	1.1	11
116	Triple-Negative Breast Cancer, Stem Cells, and African Ancestry. American Journal of Pathology, 2018, 188, 271-279.	1.9	33
117	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell, 2020, 37, 639-654.e6.	7.7	151
118	CVCDAP: an integrated platform for molecular and clinical analysis of cancer virtual cohorts. Nucleic Acids Research, 2020, 48, W463-W471.	6.5	18
119	Changing How Race Is Portrayed in Medical Education: Recommendations From Medical Students. Academic Medicine, 2020, 95, 1802-1806.	0.8	66
120	Ki67 Immunohistochemistry Quantification in Breast Carcinoma: A Comparison of Visual Estimation, Counting, and ImmunoRatio. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 105-111.	0.6	16
124	The Upper Digestive Tract Microbiome and Oesophageal Squamous Cell Carcinoma: Epidemiology, Pathogenesis, and Clinical Implications in Africa. Pathobiology, 2021, 88, 141-155.	1.9	2
125	Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies. Diabetology and Metabolic Syndrome, 2020, 12, 10.	1.2	22
126	Early Death Incidence and Prediction in Stage IV Breast Cancer. Medical Science Monitor, 2020, 26, e924858.	0.5	11
127	Using The Cancer Genome Atlas as an Inquiry Tool in the Undergraduate Classroom. Frontiers in Genetics, 2020, 11, 573992.	1.1	7
128	Trends and Disparities in Breast Cancer Incidence-Mortality Rates of Black-White Women in the U.S.: 2000-2016. Advances in Breast Cancer Research, 2021, 10, 200-217.	0.1	0
129	High expression of transmembrane P24 trafficking protein 9 predicts poor prognosis in breast carcinoma. Bioengineered, 2021, 12, 8965-8979.	1.4	8
130	Molecular Profiles of Breast Cancer in Hispanic/Latina. , 2020, , 103-109.		1

#	Article	IF	Citations
131	Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. Cancer Research, 2022, 82, 25-35.	0.4	10
136	Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity?. Journal of Surgical Research, 2020, 255, 205-215.	0.8	2
137	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nature Communications, 2021, 12, 6946.	5.8	22
138	Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities. Breast Cancer Research and Treatment, 2022, 191, 653-663.	1.1	9
139	Association of Genetic Ancestry and Molecular Signatures with Cancer Survival Disparities: A Pan-Cancer Analysis. Cancer Research, 2022, 82, 1222-1233.	0.4	11
140	Genetic Evaluation for Hereditary Cancer Syndromes Among African Americans: A Critical Review. Oncologist, 2022, 27, 285-291.	1.9	10
141	Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression. Breast Cancer Research and Treatment, 2022, 192, 447-455.	1.1	1
142	Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. Journal of Clinical Oncology, 2022, 40, 1407-1413.	0.8	17
143	The DNA damage repair landscape in Black women with breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210754.	1.4	6
144	Artificial Intelligence Comes of Age in the Fight Against Cancer. Oncology Times, 2022, 44, 1,15-16.	0.1	0
145	Breast Cancer in Black Women: Racial/Ethnic Disparities Affecting Survival. Journal of Women's Health, 2022, 31, 1255-1261.	1.5	1
146	Race-associated Molecular Changes in Gynecologic Malignancies. Cancer Research Communications, 2022, 2, 99-109.	0.7	6
147	Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Research and Treatment, 2022, 192, 639-648.	1.1	7
148	Kinesin Family Member C1 (KIFC1/HSET): A Potential Actionable Biomarker of Early Stage Breast Tumorigenesis and Progression of High-Risk Lesions. Journal of Personalized Medicine, 2021, 11, 1361.	1.1	6
149	Reduced Expression of Annexin A6 Induces Metabolic Reprogramming That Favors Rapid Fatty Acid Oxidation in Triple-Negative Breast Cancer Cells. Cancers, 2022, 14, 1108.	1.7	4
154	Wnt signaling in triple-negative breast cancers: Its roles in molecular subtyping and cancer cell stemness and its crosstalk with non-coding RNAs. Life Sciences, 2022, 300, 120565.	2.0	6
155	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression. Cancers, 2022, 14, 2148.	1.7	22
156	Expression and clinical prognostic value of CYB561 in breast cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1879-1892.	1.2	7

#	ARTICLE	IF	CITATIONS
157	Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT1-2N+ Breast Cancer Patients: A Single Center Experience and Review of Current Literature. Frontiers in Oncology, 2022, 12, .	1.3	2
158	Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells. Nutrients, 2022, 14, 2120.	1.7	6
159	Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases. Npj Breast Cancer, 2022, 8, .	2.3	1
160	The Association Between Breast Cancer and Blood-Based Methylation of CD160, ISYNA1 and RAD51B in the Chinese Population. Frontiers in Genetics, 0, 13, .	1.1	1
161	Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences. Npj Breast Cancer, 2022, 8, .	2.3	6
162	Translational Epidemiology: An Integrative Approach to Determine the Interplay Between Genetic Ancestry and Neighborhood Socioeconomic Status on Triple Negative Breast Cancer. Annals of Surgery, 2022, 276, 430-440.	2.1	11
163	Chemokine receptors differentially expressed by race category and molecular subtype in the breast cancer TCGA cohort. Scientific Reports, 2022, 12, .	1.6	5
164	Emerging Trends in Bioinformatics for Breast Cancer Molecular Research. , 2022, , 86-108.		0
165	Patients with Lung Cancer of Different Racial Backgrounds Harbor Distinct Immune Cell Profiles. Cancer Research Communications, 2022, 2, 884-893.	0.7	6
166	Breast Carcinoma Receptor Expression in a Caribbean Population. The Surgery Journal, 2022, 08, e262-e265.	0.3	0
168	Breast Cancer Statistics, 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 524-541.	157.7	611
169	Race and Ancestry in Immune Response to Breast Cancer. Cancer Discovery, 2022, 12, 2496-2497.	7.7	1
170	CLINICOPATHOLOGICAL FEATURES OF BREAST CARCINOMA WITH DIFFERENT MOLECULAR SUBTYPES IN MOROCCAN WOMEN, DATA ABOUT 1040 CASES. , 2022, , 25-28.		1
171	Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2023, 198, 75-88.	1.1	5
172	Genetic variants in African‑American and Hispanic patients with breast cancer. Oncology Letters, 2022, 25, .	0.8	0
173	Association of genetic ancestry with HER2, GRB7 AND estrogen receptor expression among Colombian women with breast cancer. Frontiers in Oncology, 0, 12, .	1.3	2
174	Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population. Cancer Research Communications, 2023, 3, 12-20.	0.7	1
175	Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations. Clinical Cancer Research, 2023, 29, 1194-1199.	3.2	0

#	ARTICLE	IF	CITATIONS
176	Kernel Mean Matching with Mahalanobis Distance for Causal Inference of Time-to-event Outcome. , 2022, , .		0
177	Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer. Frontiers in Medicine, 0, 10, .	1.2	2
179	Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer. Breast Cancer Research and Treatment, 2023, 199, 1-12.	1.1	4
180	Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. Oncologist, 2023, 28, 319-326.	1.9	1
182	Fibroblasts as Turned Agents in Cancer Progression. Cancers, 2023, 15, 2014.	1.7	13
183	Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Network Open, 2023, 6, e233329.	2.8	13
184	Clear cell renal cell carcinoma molecular variations in <scp>non‐Hispanic</scp> White and Hispanic patients. Cancer Medicine, 2023, 12, 12792-12801.	1.3	0
197	Opportunities, Challenges, and Priorities for Achieving Equity in Cancer Outcomes. , 2023, , 183-202.		0